{
  "docId": "019de076-341d-707d-8f10-e094a3d9771c",
  "docSlug": "c0c2a81b97260bf20014943df2470872",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 39,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a column-based layout to compare four distinct disease indications.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-341d-707d-8f10-e094a3d9771c/18",
  "deckHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c",
  "deckJsonHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c.json",
  "deckAnchorHref": "/decks/019de076-341d-707d-8f10-e094a3d9771c#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Multi-Billion dollar market opportunity for EQ101 in medical dermatology. Large need exists for safe and effective therapies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "239af9d8-1b0f-4246-b0ad-a14b233bc4ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "Cutaneous T cell Lymphoma: 24,000 adult US Patients; PoC Achieved, Phase 2/3 Ready, Open IND, Unmet need for safe and effective therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c0f61dc-9248-4427-95fb-9ba03ad320bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.72,
        "y": 0.35
      },
      "kind": "list",
      "text": "Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity, 3 FDA approved JAKi, Large refractory population in need of safe treatment alternatives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf4ab133-32ca-4fcb-a322-1e4a3474abc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.49,
        "y": 0.35
      },
      "kind": "list",
      "text": "Vitiligo: 1.5M+ US Patients; Future Opportunity, Only one FDA approval: JAKi, Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d25b0622-d0d3-414d-b644-08e2b8547772",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.26,
        "y": 0.35
      },
      "kind": "list",
      "text": "Alopecia Areata: 250,000 US moderate-severe Patients; Phase 2 Study ongoing, Only two FDA approvals: JAKi, Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f98231d2-87d9-46c8-9904-51322cbe222b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1) Kx Advisors 2) Benigno, Clin Cosmet Investig Dermatol, 2020 3) Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020 4) Chiesa Fuxench ZC, J Invest Dermatol. 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8baf1b51-b37e-4d81-85cc-701ec3e580fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "EQ101: Valuable Medical Dermatology Franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef3f9db2-b614-4d28-95cc-6368a981d5fa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 18,
      "beatId": "c2be1031-ac04-43ce-b024-d0e129b5699a",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Market sizing is discussed on page 18.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}